Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2013

View Archived Issues

ASP-1017FM has potentially beneficial effects on migraine

Hanmi Science discloses new protein kinase inhibitors for cancer

Pulmatrix commences phase Ib COPD study

Novel agents for metabolic diseases disclosed by Cadila Healthcare

Genmab submits IND to conduct phase I study of HuMax-TF-ADC

Gilead Sciences presents novel agents for HIV infection

Researchers at Rutgers disclose new antibacterial RNA polymerase inhibitors

Daiichi Sankyo and Ube Industries synthesize new CETP inhibitors

Experiments profile preclinical activity of Alzheimer's disease candidate AZD-3293

Novel drug and drug target for the treatment of addictive disorders characterized

Noven Pharmaceuticals reports topline results from phase II d-ATS

Results of a phase I evaluation of antigen-specific tolerance for multiple sclerosis

Ligand signs license agreement with Azure Biotech for lasofoxifene

New biomaterial coatings to improve bone-bioimplant interface stability

Cellular Biomedicine begins phase I trial of adipose-derived mesenchymal progenitor cells

Johnson & Johnson reviews second quarter 2013

Aquinox begins dosing in phase II trial of AQX-1125 in BPS/IC

Protalex continues enrollment in phase Ib trial of PRTX-100 following third interim review

Mast Therapeutics' QT study of MST-188 meets primary endpoint

Charleston Laboratories completes pre-IND meeting regarding migraine treatment

Phase III trial comparing obinutuzumab to Rituxan in CLL meets primary endpoint

Arrowhead commences phase I trial of RNAi therapeutic

Quest PharmaTech and AD Biotech form joint venture

Trovagene's reports validation of assay for detecting BRAF mutation in urine

Roche launches new drug monitoring tests for immunosuppressive therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...